The unmet need in rheumatology: Reports from the targeted therapies meeting 2017

Kevin Winthrop, Vibeke Strand, Désirée van der Heijde, Philip Mease, Mary Crow, Michael Weinblatt, Joan Bathon, Gerd R. Burmester, Maxime Dougados, Johnathan Kay, Xavier Mariette, Ronald Van Vollenhoven, Joachim Sieper, Fritz Melchers, Ferdinand C. Breedfeld, Joachim Kalden, Josef S. Smolen, Daniel E. Furst

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e.g. Sjogren's syndrome, Systemic sclerosis, vasculitis including Bechet's and IgG4 related disease), and a basic science immunology group spanning all of the above clinical domains. In each group, experts were asked to consider and update previously identified unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Overall, similar primary unmet needs were identified within each disease foci, and several additional needs were identified since the time of last year's congress. Within translational/basic science, the need for better understanding the heterogeneity within each disease was highlighted so that predictive tools for therapeutic responses can be developed. Within clinical science and therapeutic trials, a strong focus was placed upon the need to identify pre-clinical states of disease allowing prevention in those at risk. The ability to cure remains perhaps the ultimate unmet need. Further, the need to develop new and affordable therapeutics, as well as to conduct strategic trials of currently approved therapies was again highlighted. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterized, longitudinal cohorts paired with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.

Original languageEnglish (US)
JournalClinical Immunology
DOIs
StateAccepted/In press - 2017

Fingerprint

Rheumatology
Allergy and Immunology
Therapeutics
Systemic Vasculitis
Patient-Centered Care
Psoriatic Arthritis
Connective Tissue Diseases
Information Dissemination
Systemic Scleroderma
Sjogren's Syndrome
Molecular Biology
Rheumatoid Arthritis
Immunoglobulin G
Research Personnel
Morbidity

Keywords

  • Ankylosing spondylitis
  • Inflammatory myopathies
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Sjögren's syndrome
  • Spondyloarthritis
  • Systemic lupus erythematosus
  • Systemic sclerosis
  • Vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Winthrop, K., Strand, V., van der Heijde, D., Mease, P., Crow, M., Weinblatt, M., ... Furst, D. E. (Accepted/In press). The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clinical Immunology. https://doi.org/10.1016/j.clim.2017.08.009

The unmet need in rheumatology : Reports from the targeted therapies meeting 2017. / Winthrop, Kevin; Strand, Vibeke; van der Heijde, Désirée; Mease, Philip; Crow, Mary; Weinblatt, Michael; Bathon, Joan; Burmester, Gerd R.; Dougados, Maxime; Kay, Johnathan; Mariette, Xavier; Van Vollenhoven, Ronald; Sieper, Joachim; Melchers, Fritz; Breedfeld, Ferdinand C.; Kalden, Joachim; Smolen, Josef S.; Furst, Daniel E.

In: Clinical Immunology, 2017.

Research output: Contribution to journalArticle

Winthrop, K, Strand, V, van der Heijde, D, Mease, P, Crow, M, Weinblatt, M, Bathon, J, Burmester, GR, Dougados, M, Kay, J, Mariette, X, Van Vollenhoven, R, Sieper, J, Melchers, F, Breedfeld, FC, Kalden, J, Smolen, JS & Furst, DE 2017, 'The unmet need in rheumatology: Reports from the targeted therapies meeting 2017', Clinical Immunology. https://doi.org/10.1016/j.clim.2017.08.009
Winthrop, Kevin ; Strand, Vibeke ; van der Heijde, Désirée ; Mease, Philip ; Crow, Mary ; Weinblatt, Michael ; Bathon, Joan ; Burmester, Gerd R. ; Dougados, Maxime ; Kay, Johnathan ; Mariette, Xavier ; Van Vollenhoven, Ronald ; Sieper, Joachim ; Melchers, Fritz ; Breedfeld, Ferdinand C. ; Kalden, Joachim ; Smolen, Josef S. ; Furst, Daniel E. / The unmet need in rheumatology : Reports from the targeted therapies meeting 2017. In: Clinical Immunology. 2017.
@article{3e3ed02a71db4b0c9418d15d1b181d5c,
title = "The unmet need in rheumatology: Reports from the targeted therapies meeting 2017",
abstract = "The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e.g. Sjogren's syndrome, Systemic sclerosis, vasculitis including Bechet's and IgG4 related disease), and a basic science immunology group spanning all of the above clinical domains. In each group, experts were asked to consider and update previously identified unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Overall, similar primary unmet needs were identified within each disease foci, and several additional needs were identified since the time of last year's congress. Within translational/basic science, the need for better understanding the heterogeneity within each disease was highlighted so that predictive tools for therapeutic responses can be developed. Within clinical science and therapeutic trials, a strong focus was placed upon the need to identify pre-clinical states of disease allowing prevention in those at risk. The ability to cure remains perhaps the ultimate unmet need. Further, the need to develop new and affordable therapeutics, as well as to conduct strategic trials of currently approved therapies was again highlighted. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterized, longitudinal cohorts paired with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.",
keywords = "Ankylosing spondylitis, Inflammatory myopathies, Psoriatic arthritis, Rheumatoid arthritis, Sj{\"o}gren's syndrome, Spondyloarthritis, Systemic lupus erythematosus, Systemic sclerosis, Vasculitis",
author = "Kevin Winthrop and Vibeke Strand and {van der Heijde}, D{\'e}sir{\'e}e and Philip Mease and Mary Crow and Michael Weinblatt and Joan Bathon and Burmester, {Gerd R.} and Maxime Dougados and Johnathan Kay and Xavier Mariette and {Van Vollenhoven}, Ronald and Joachim Sieper and Fritz Melchers and Breedfeld, {Ferdinand C.} and Joachim Kalden and Smolen, {Josef S.} and Furst, {Daniel E.}",
year = "2017",
doi = "10.1016/j.clim.2017.08.009",
language = "English (US)",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The unmet need in rheumatology

T2 - Reports from the targeted therapies meeting 2017

AU - Winthrop, Kevin

AU - Strand, Vibeke

AU - van der Heijde, Désirée

AU - Mease, Philip

AU - Crow, Mary

AU - Weinblatt, Michael

AU - Bathon, Joan

AU - Burmester, Gerd R.

AU - Dougados, Maxime

AU - Kay, Johnathan

AU - Mariette, Xavier

AU - Van Vollenhoven, Ronald

AU - Sieper, Joachim

AU - Melchers, Fritz

AU - Breedfeld, Ferdinand C.

AU - Kalden, Joachim

AU - Smolen, Josef S.

AU - Furst, Daniel E.

PY - 2017

Y1 - 2017

N2 - The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e.g. Sjogren's syndrome, Systemic sclerosis, vasculitis including Bechet's and IgG4 related disease), and a basic science immunology group spanning all of the above clinical domains. In each group, experts were asked to consider and update previously identified unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Overall, similar primary unmet needs were identified within each disease foci, and several additional needs were identified since the time of last year's congress. Within translational/basic science, the need for better understanding the heterogeneity within each disease was highlighted so that predictive tools for therapeutic responses can be developed. Within clinical science and therapeutic trials, a strong focus was placed upon the need to identify pre-clinical states of disease allowing prevention in those at risk. The ability to cure remains perhaps the ultimate unmet need. Further, the need to develop new and affordable therapeutics, as well as to conduct strategic trials of currently approved therapies was again highlighted. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterized, longitudinal cohorts paired with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.

AB - The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e.g. Sjogren's syndrome, Systemic sclerosis, vasculitis including Bechet's and IgG4 related disease), and a basic science immunology group spanning all of the above clinical domains. In each group, experts were asked to consider and update previously identified unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Overall, similar primary unmet needs were identified within each disease foci, and several additional needs were identified since the time of last year's congress. Within translational/basic science, the need for better understanding the heterogeneity within each disease was highlighted so that predictive tools for therapeutic responses can be developed. Within clinical science and therapeutic trials, a strong focus was placed upon the need to identify pre-clinical states of disease allowing prevention in those at risk. The ability to cure remains perhaps the ultimate unmet need. Further, the need to develop new and affordable therapeutics, as well as to conduct strategic trials of currently approved therapies was again highlighted. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterized, longitudinal cohorts paired with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.

KW - Ankylosing spondylitis

KW - Inflammatory myopathies

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

KW - Sjögren's syndrome

KW - Spondyloarthritis

KW - Systemic lupus erythematosus

KW - Systemic sclerosis

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85028377533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028377533&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2017.08.009

DO - 10.1016/j.clim.2017.08.009

M3 - Article

C2 - 28811201

AN - SCOPUS:85028377533

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -